Aquinox Pharmaceuticals has completed the list of candidates to be included in the clinical trial of its bladder pain syndrome treatment, rosiptor. The company on Friday said it remains on track for the top line results from second half of the year.The company announced it as part of its analyst and investor event held in New York.
“Hitting our enrollment target is a key milestone in our clinical development plan for rosiptor, our lead drug candidate, and we continue to be on track to share topline data from LEADERSHIP 301 in the third quarter of 2018,” said David Main, President & CEO of Aquinox.
“We believe the majority of patients with IC/BPS don’t have effective treatment options today. We’re excited for the role rosiptor may be able to play in offering hope to the millions of adults with IC/BPS and look forward to sharing the results of this clinical trial.”